CDK14 and synucleinopathy: Finally, pharmacological targeting of CDK14 lowers pathological α-Syn in cultured neurons and modifies pathogenic forms of α-Syn in mice expressing PD-linked human A53T SNCA. Taken together, we propose CDK14 inhibition as a novel pre-clinical strategy to modify the progression of synucleinopathies.